Perceives Failure
"If I'm put on insulin, I must be doing something wrong."
- Perceives Failure

About 40% of diabetes patients nationwide were not at an A1C goal of <7% with OADs.1

You may want to have the insulin talk sooner

Millions of People with Diabetes Have Blood Sugar that may be Uncontrolled.1

Rethinkinsulin.com Statistically, 4 out of 10 of your patients on OADs may not be at goal

Research from 2003-2004 showed that about 40% of patients nationwide (approximately 9 million people) were not at an A1C goal of <7% with OADs.1 As part of an overall diabetes treatment program, insulin may be a suitable option for controlling blood glucose levels.

Timely initiation of insulin for your appropriate patients with T2DM is an effective way to lower blood glucose.2

  • Insulin is an effective medication to lower blood glucose.3
Rethinkinsulin.com Rethinkinsulin.com OAD_chart_1.0
Next >

Important Safety Information for Lantus®

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and precautions

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Drug interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse reactions

Other adverse reactions commonly associated with Lantus® are injection site reaction, lipodystrophy, pruritus, and rash.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Indications and Usage for Lantus®

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Please click here for full prescribing information

References: 1. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Diabetes Care. 2008;31(1):81-86.
2. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. Endocr Pract. 2007;
13(suppl 1):4-68
3. Nathan DM et al. Diabetes Care. 2009;32(1):193-203.